| News Releases |
Study confirms breast cancer chemo benefit, but gene test may ID patients not helped
[Dec. 10, 2009]
|
Chemotherapy added to tamoxifen can improve outcomes for postmenopausal breast cancer patients, according to a landmark study by the Southwest Oncology Group. But a related study finds that a multigene test on tumors can identify a subset of patients who may not benefit from that chemotherapy.
|
| |
$4 million NCI grant funds comparative effectiveness research at Southwest Oncology Group
[Oct. 15, 2009]
|
|
Launched with federal stimulus funds, new CANCERGEN center’s vision is to make Southwest Oncology Group a national leader in cancer comparative effectiveness research.
|
| |
Five chosen for SWOG Young Investigator course
[Sep. 14, 2009]
|
Five talented researchers who are early in their career will attend a three-day Southwest Oncology Group workshop for intensive training in how to design and conduct cancer clinical trials.
|
| |
| To News Releases Archive |
| |
| SWOG in the News |
New U Tenn SWOG affiliate cited
[Sep. 28, 2009]
|
|
The Cookeville Times of Tennessee recognized the Cookeville Regional Cancer Center for its recent affiliation with SWOG through the University of Tennessee Health Care System.
|
| |
IASLC: Four-Drug Therapy for NSCLC Appears Well Tolerated
[Aug. 3, 2009]
|
|
MedPage Today reported on a presentation by Edward Kim, M.D., of M.D. Anderson Cancer Center, to the world conference of the International Association for the Study of Lung Cancer (IASLC) in San Francisco. Kim presented an abstract on the the results of S0536, a SWOG phase II study on the feasibility of using a four-drug regimen that includes cetuximab in the treatment of advanced non-small cell lung cancer. SWOG study S0819 has just been activated based in part on the S0536 results Kim reported on.
|
| |
| To SWOG in the News Archive
|
| |
